Cancer Treatment Reviews
Volume 28, Issue 6 , Pages 305-319 , December 2002

The anti-tumour activity of bisphosphonates

  • H.L Neville-Webbe

      Affiliations

    • Department of Clinical Oncology, Cancer Research Centre, Sheffield S10 2SJ, UK
    • Corresponding Author InformationCorrespondence to: H. L. Neville-Webbe, Clinical Research Fellow, Department of Clinical Oncology, Cancer Research Centre, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ, UK. Tel.: +44-114-226-5000; Fax: +44-114-271-3781
    • ,
  • I Holen

      Affiliations

    • Division of Genomic Medicine, Cancer Research Centre, Sheffield S10 2SJ, UK
    • ,
  • R.E Coleman

      Affiliations

    • Medical Oncology, Cancer Research Centre, Sheffield S10 2SJ, UK

References 

  1. Russell RGG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back and again. Bone. 1999;25:97–106
  2. Amin D, Cornell SA, Gustafson SK, et al.  Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J. Lipid. Res. 1992;33:1657–1663
  3. Rogers MJ, Brown RJ, Hodkin V, et al.  Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem. Biophys. Res. Commun. 1996;224:863–869
  4. Kanis JA, Powles T, Patterson AHG, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 1996;19(6):663–667
  5. McCloskey EV, Dunn JA, Kanis JA, MacLennan IC, Drayson MT. Long-term follow-up of a prospective, double-blind, placebo-controlled randomised trial of clodronate in multiple myeloma. Br. J. Haemotol. 2001;113:1035–1043
  6. Powles TJ, Patterson S, Kanis JA, et al.  Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J. Clin. Oncol. 2002;20:3219–3224
  7. Diel IJ, Solomayer EF, Costa S, et al.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl. J. Med. 1998;339:357–363
  8. Diel IJ, Kaufman M, Goerner R, Costa SD, Kaul S, Bastert G. Detection of tumour cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J. Clin. Oncol. 1992;10:1534–1539
  9. Diel IJ, Solomayer E-F, Gollan C, Schutz F, Bastert G. Bisphosphonates in the reduction of metastases in breast cancer-results of the extended follow-up lf the first study population. Pro Am Soc Clin Oncol 2000; Abstract 314
  10. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomised controlled trial. J. Clin. Oncol. 2001;19(1):10–17
  11. Mardiak J, Bohunicky L, Chovanec J, Salek T, Koza I. Adjuvant clodronate therapy in patients with locally advanced breast cancer-long term results of a double blind randomised trial. Slovak Clodronate Collaborative Group. Neoplasma. 2000;47(3):177–180
  12. Mundy G. Preclinical models of bone metastases. Semin. Oncol. 2001;28(4, Suppl 11):2–8
  13. Sasaki A, Boyce BF, Story B, et al.  Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 1995;55:3551–3557
  14. Sasaki A, Kitamura K, Alcalde RE, et al.  Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int. J. Cancer. 1998;77:279–285
  15. Krempien B, Manegold C. Prophylactic treatment of skeletal metastases, tumour-induced osteolysis, and hypercalcaemia in rats with the bisphosphonate Cl2MBP. Cancer. 1993;72:91–98
  16. Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment. Semin. Oncol. 2001;28(2, Suppl 6):35–44
  17. Kostenuik PJ, Orr FW, Suyama K, et al.  Increased growth rate and tumour burden of spontaneously metastatic Walker 256 cancer cells in the skeleton of bisphosphonate-treated rats. Cancer Res. 1993;53:5452–5457
  18. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer. 2000;88:2892–2898
  19. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J. Clin. Invest. 1996;98(3):698–705
  20. van der Pluijm G, Kerr J, Lowik C, Gehron Robey P. β1 and β3 integrin subunits are involved in adhesion of breast cancer cells to extracellular bone matrix. J Bone Miner Res 1993; 8: Absract S136
  21. Boissier S, Magnetto S, Frappart L, et al.  Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralised and mineralised bone extracellular matrices. Cancer Res. 1997;57(18):3890–3894
  22. Virtanen SS, Väänänen HK, Härkönene PL, Lakkakorpi PT. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res. 2002;62:2708–2714
  23. Boissier S, Ferreras M, Peyruchaud O, et al.  Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60:2949–2954
  24. Teronen O, Heikkila P, Konttinen YT, et al.  MMP inhibition and downregulation by bisphosphonates. Ann. N. Y. Acad. Sci. 1999;878:453–465
  25. Shipman CM, Croucher PI, Russell RG, Helfrich MH, Rogers MJ. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 1998;58(23):5294–5297
  26. Dunford JE, Thompson K, Coxon FP, et al.  Structure activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol Exp Ther. 2000;296(2):235–242
  27. Rogers MJ, Gordon S, Benford HL, et al.  Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88:2961–2978
  28. Benford HL, McGowan NW, Helfrich MH, Nutall ME, Rogers MJ. Visualisation of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone. 2001;28(5):465–473
  29. Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997;326:1–16
  30. Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J. Cancer. 2001;84(8):1126–1134
  31. Zou H, Henzel WJ, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegance CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 1997;90:405–413
  32. Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells. Br. J. Cancer. 2002;86:1479–1486
  33. Benford HL, Frith JC, Auriola S, Monkkonen J, Rogers MJ. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol. Pharm. 1999;56:131–140
  34. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J. Cancer. 2000;82(8):1459–1468
  35. Boise LH, Gonzalez-Garcia M, Postema CE, et al.  Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell. 1993;74:597–608
  36. Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res. 2001;61:4418–4424
  37. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001;61:2602–2608
  38. Crohns CA, Untch M, Konecny G. Different bisphosphonates have direct cytotoxic effects on three breast cancer cell lines and fresh breast cancer tumour tissue. Proc Am Soc Clin Oncol 2001; Abstract 2005
  39. Mackie PS, Fisher JL, Zhou H, Choong PF. Bisphosphonates regulate cell growth and gene expression in the Umr 106-01 clonal rat osteosarcoma cell line. Br. J. Cancer. 2001;84(7):951–958
  40. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W, van Valen F. The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs. 2001;12(5):459–465
  41. Duffy MJ, Maguire TM, Hill A, McDermott E, O’Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000;2(4):252–257
  42. Heikkila P, Teronen O, Moilanen M, et al.  Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs. 2002;13(3):245–254
  43. Derenne S, Amiot M, Barille S, et al.  Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J. Bone Miner Res. 1999;14(12):2048–2056
  44. Yoneda T, Sasaki A, Dunstan C, et al.  Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J. Clin. Invest. 1997;99(10):2509–2517
  45. Locopo N, Fanelli M, Gasparini G. Clinical significance of angiogenic factors in breast cancer. Breast Cancer Res. Treat. 1998;52:159–173
  46. Zachary I, Gliki G. Signalling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res. 2001;49:568–581
  47. Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, et al  Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000;60:2898–2905
  48. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J. Cancer. 2001;85(2):273–278
  49. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, et al.  Prognostic significance of vascular endothelial growth factor protein in node-negative breast cancer. J. Natl. Cancer Inst. 1997;89:139–147
  50. Linderholm B, Tavelin B, Grankvist K, Henriksson R. Vascular endothelial growth factor is of high prognostic value in node-negative carcinoma. J. Clin. Oncol. 1998;16:3121–3128
  51. Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, et al.  High tumour levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res. 2001;61:5407–5414
  52. Faridi A, Rudlowski C, Biesterfeld S, Schuh S, Rath W, Schroder W. Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer. Pathol. Res. Pract. 2002;198(1):1–5
  53. Bellahcene V, Bonjean K, Fohr B, Fedarko NS, Robey FA, Young MF, et al. Bone sialoprotein mediates human endothelial cell attachment and migration and promotes angiogenesis. Circ. Res. 2000;86:885–891
  54. Jagdev SP, Croucher PI, Coleman RE. The effects of intravenous bisphosphonate treatment on the bone microenvironment in patients with breast cancer and bone metastases. European J. Cancer. 2001;37(6):S129
  55. Santini D, Vincenzi B, Avvisati G, et al.  Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin. Cancer Res. 2002;8:1080–1084
  56. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al.  Novel anti-angiogenic effects of the bisphosphonates compound zoledronic acid. JPET. 2002;302(3):1055–1061
  57. Sterns ME, Wang M. Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis. 1996;16(3):116–131
  58. Magnetto S, Boissier S, Delmas PD, Clezardin P. Additive anti-tumour activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int. J. Cancer. 1999;83:263–269
  59. Jagdev SP, Croucher PI, Coleman RE. Zoledronate induces apoptosis of breast cancer cells in vitro-evidence for additive and synergistic effects with taxol and tamoxifen. Proc Am Soc Clin Oncol 2000; Abstract 2619
  60. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer. 2000;88:2979–2988
  61. Tassone P, Forciniti S, Galea E, et al.  Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukaemia. 2000;14:841–844
  62. Witters L, Crispino J, Javeed M, et al. Inhibition of growth of a human prostate cancer cell line with the combination of zoledronic acid and a COX-2 inhibitor. Proc Am Soc Clin Oncol 2002; Abstract 1827
  63. Parrett ML, Harris RE, Joarder FS, et al.  Cyclo-oxygenase-2 gene expression in human breast cancer. Int J. Oncol. 1997;10:503–507
  64. Gupta S, Srivastava M, Ahmad N, et al.  Over-expression of cyclo-oxygenase-2 in human prostate adenocarcinoma. Prostate. 2000;42:73–78
  65. Gallo O, Franchi A, Magnelli L, et al.  Cyclo-oxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumour angiogenesis and metastasis. Neoplasia. 2001;3:53–61
  66. Hsu AL, Ching TT, Wang DS, et al.  The cyclo-oxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of bcl-2. J. Biol. Chem. 2000;275:11397–11403
  67. Brueggemeier RW, Quinn AL, Parrett ML, et al.  Correlation of aromatase and cyclo-oxygenase gene expression in human breast cancer specimens. Cancer Lett. 1999;140:27–35
  68. Michael MD, Michael LF, Simpson ER. A CRE-like sequence that binds CREB and contributes to camp-dependent regulation of the proximal promoter of the human aromatase P450 (CYP19) gene. Mol. Cell Endocrinol. 1997;134:147–156
  69. Rolland PH, Martin PM, Jacquemier J, et al.  Prostaglandin in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J. Natl. Cancer Inst. 1980;64:1061–1070
  70. Liu XH, Rose DP. Differential expression and regulation of cyclo-oxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res. 1996;56:5125–5127
  71. Sauty A, Pecherstofer M, Simmer-Roth I, et al.  Interleukin-6 and tumour necrosis factor α levels after bisphosphonate treatment in vitro and in patients with malignancy. Bone. 1996;18(2):133–139

PII: S0305-7372(02)00095-6

Cancer Treatment Reviews
Volume 28, Issue 6 , Pages 305-319 , December 2002

Article Tools

* Image Usage & Resolution